Opticyte has been capital-efficient and funded with non-dilutive grants and angel investments. The company has issued patents, a clear FDA De Novo pathway and Breakthrough Device Designation, and the potential to deliver significant cost savings to hospitals. Demonstrating strong momentum and credibility, Opticyte is a medical device innovator to watch.
The company is currently raising Series A. Milestones include product development, FDA clearance, and initial sales.